At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 128 enrolled
Drug / intervention
ALD403 (Eptinezumab)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Phase 3 Trial to Evaluate the Safety of ALD403 Administered Intravenously in Patients With Chronic Migraines
In Brief
A Phase 3 clinical trial evaluating ALD403 (Eptinezumab) for Migraine Disorder. Completed, enrolled 128 participants across 20 sites.
Detailed Summary
An evaluation of long term safety of repeat ALD403 doses in Chronic Migraine
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartDec 2016
First PostedDec 2016
Primary CompletionApr 2018
Study CompletionMar 2019
TodayJul 2026
First PostedDec 7, 2016
Enrollment StartDec 1, 2016
Primary CompletionApr 1, 2018
Study CompletionMar 1, 2019
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 9.6 years ago
Interventions
ALD403 (Eptinezumab)biological